Simulect and Cozaar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Simulect and Cozaar. Common interactions include abdominal wall abscess among females and toxic optic neuropathy among males.

The phase IV clinical study analyzes what interactions people who take Simulect and Cozaar have. It is created by eHealthMe based on reports of 9 people who take Simulect and Cozaar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

9 people who take Simulect and Cozaar together, and have interactions are studied.


What is Simulect?

Simulect has active ingredients of basiliximab. eHealthMe is studying from 3,526 Simulect users for its effectiveness, alternative drugs and more.

What is Cozaar?

Cozaar has active ingredients of losartan potassium. It is often used in high blood pressure. eHealthMe is studying from 42,226 Cozaar users for its effectiveness, alternative drugs and more.

Number of Simulect and Cozaar reports submitted per year:

Simulect and Cozaar drug interactions.

Common Simulect and Cozaar drug interactions by gender *:

female:

  1. Abdominal wall abscess
  2. Bacterial infection
  3. Blood creatinine increased
  4. Blood glucose increased
  5. Dysphagia
  6. Erythema
  7. Induration
  8. Localised intraabdominal fluid collection
  9. Pyrexia
  10. Tenderness

male:

  1. Toxic optic neuropathy
  2. Anaemia
  3. Headache
  4. Hyperkalaemia
  5. Hypophosphataemia
  6. Leukopenia
  7. Muscular weakness
  8. Myocardial infarction
  9. Nephrogenic systemic fibrosis
  10. Oedema peripheral

Common Simulect and Cozaar drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Toxic optic neuropathy
  2. Anaemia
  3. Blood creatinine increased
  4. Dizziness
  5. Gastrointestinal haemorrhage
  6. Headache
  7. Leukopenia
  8. Nephrogenic systemic fibrosis

50-59:

n/a

60+:

  1. Atelectasis
  2. Myocardial infarction
  3. Localised intraabdominal fluid collection
  4. Pyrexia
  5. Tenderness
  6. Wound secretion
  7. Anaemia
  8. Anaphylactic shock
  9. Atrial thrombosis
  10. Bradycardia

* Approximation only. Some reports may have incomplete information.

Do you take Simulect and Cozaar?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Simulect and Cozaar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Simulect interactions:

Browse all interactions between Simulect and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Cozaar interactions:

Browse all interactions between Cozaar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on basiliximab and losartan potassium (the active ingredients of Simulect and Cozaar, respectively), and Simulect and Cozaar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Simulect and Cozaar.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: